IDEXX Laboratories Reports Strong Q4 Earnings and 2026 Revenue Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2025
0mins
Should l Buy IDXX?
Source: Business Insider
IDEXX Laboratories' stock fell 3.78% and hit a 20-day low amid a generally positive market, with the Nasdaq-100 up 0.17% and the S&P 500 up 0.05%.
The company reported a Q4 non-GAAP EPS of $3.01, exceeding expectations by $0.07, and achieved Q4 revenue of $1.09 billion, reflecting a 14.3% year-over-year increase. IDEXX also provided a positive revenue outlook for 2026, projecting revenue between $4.632 billion and $4.720 billion, indicating strong demand in the diagnostics sector. Despite the strong earnings report, the stock price declined, likely due to sector rotation as investors shifted focus to other areas of the market.
The strong earnings and positive guidance suggest that IDEXX remains well-positioned in the diagnostics market, but the stock's decline may present a buying opportunity for investors looking to capitalize on its growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDXX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDXX
Wall Street analysts forecast IDXX stock price to rise
10 Analyst Rating
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 598.850
Low
750.00
Averages
792.78
High
850.00
Current: 598.850
Low
750.00
Averages
792.78
High
850.00
About IDXX
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BAMCO Reduces Stake in Vail Resorts
- Share Reduction Details: According to a SEC filing dated February 17, 2026, BAMCO Inc sold 892,764 shares of Vail Resorts during Q4, reducing its holdings to 4,809,928 shares, with a quarter-end valuation decline of $214.19 million reflecting both trading activities and price movements.
- Asset Management Ratio Shift: Following this sale, Vail Resorts now represents only 1.73% of BAMCO's 13F reportable AUM, indicating investor concerns regarding the resilience of high-end vacation spending in an uncertain travel environment.
- Company Financial Overview: As of February 17, 2026, Vail Resorts' stock price stood at $137.75, down 8.9% over the past year, underperforming the S&P 500 by 23.36 percentage points, which reflects market caution regarding its future growth prospects.
- Profitability Model Analysis: Vail Resorts generates revenue primarily from lift ticket sales, lodging, and ancillary resort services; while the Epic Pass offers predictable cash flow, the company's high fixed costs mean that even slight declines in visitor numbers can significantly pressure earnings.
See More
BAMCO Inc Sells Shares of Vail Resorts
- Share Sale Details: BAMCO Inc sold 892,764 shares of Vail Resorts in Q4 for approximately $131.38 million, reflecting market concerns about high-end vacation spending, which has led to a decline in the company's investment position.
- Value Decline: The transaction resulted in a $214.19 million decrease in BAMCO's position value in Vail Resorts, with the current holding of 4,809,928 shares valued at $638.76 million, indicating pressure on the company within the luxury travel market.
- Portfolio Impact: Vail Resorts now represents 1.73% of BAMCO's 13F reportable assets under management, no longer being among the top five holdings, which suggests a weakening investor confidence in the company.
- Market Performance Analysis: As of February 17, 2026, Vail Resorts' stock price stood at $137.75, down 8.9% over the past year, underperforming the S&P 500 by 23.36 percentage points, reflecting a cautious market outlook on its future growth.
See More
Al Gore's Investment Firm Acquires Spotify Shares and Divests from Analog Devices
- Investment Changes: Generation Investment Management, co-founded by Al Gore, exited two semiconductor companies in Q4.
- New Acquisitions: The firm invested in shares of a trending streaming provider during the same period.
See More
Idexx Laboratories: A New Opportunity in Pet Health Investment
- Consistent Investment Returns: Since 1994, Idexx Laboratories has achieved an annual return of 20%, transforming an initial $5,000 investment into $1.6 million, demonstrating its strong performance and long-term investment potential in the pet health sector.
- Innovative Products Driving Revenue: The InVue DX instrument, successfully launched in 2025, saw nearly 6,400 placements within the year, expected to become one of the company's key products, particularly in the area of pet cancer detection, further driving revenue growth.
- Stable Recurring Revenue: In the most recent quarter, 92% of sales from Idexx's consumer animal group came from recurring revenue, ensuring stable cash flow and laying a solid foundation for future growth.
- Future Growth Potential: Idexx anticipates sales, earnings per share, and recurring revenue growth of 10%, 14%, and 8% respectively in 2025, and despite a current P/E ratio of 43, its stability and ongoing growth make it a compelling long-term investment.
See More
IDEXX Laboratories Reports Strong Q4 2025 Earnings Amid Target Revisions
- Strong Performance: IDEXX Laboratories reported Q4 2025 revenue of $1.09 billion, a 14% increase year-over-year, surpassing analyst expectations of $1.072 billion, demonstrating robust performance in the medical technology sector.
- Earnings Per Share Growth: The company’s earnings per share rose 18% to $3.08, exceeding the market estimate of $2.93, reflecting its sustained profitability and a gross margin of 61.7%.
- Core Business Growth: The companion animal segment grew 15% to $998 million, driven by strong instrument revenue, which surged 76% year-over-year, indicating robust market demand.
- Cautious Future Outlook: While IDEXX expects 2026 revenue between $4.63 billion and $4.72 billion, BTIG analysts noted a 200-basis-point drag from fewer pet visits among lower-income owners, although a 4% global price growth is anticipated.
See More
IDXX Options Trading Analysis and Risks
- Options Selling Risk: Selling puts on IDXX does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, necessitating careful risk-reward assessment.
- Yield Analysis: If IDXX's stock does not fall by 11.5%, the put seller only earns an 8.5% annualized return, with an effective cost basis of $540 per share after accounting for transaction costs.
- Historical Volatility: IDXX's historical volatility stands at 41%, and when combined with fundamental analysis, it aids investors in determining whether selling puts at the $560 strike price is worthwhile, balancing risks against potential rewards.
- Market Trading Dynamics: On Friday, the put volume among S&P 500 components reached 1.33 million contracts, matching call volume, indicating higher demand for puts than the long-term median, reflecting investor expectations of market volatility.
See More
BAMCO Reduces Stake in Vail Resorts
- Share Reduction Details: According to a SEC filing dated February 17, 2026, BAMCO Inc sold 892,764 shares of Vail Resorts during Q4, reducing its holdings to 4,809,928 shares, with a quarter-end valuation decline of $214.19 million reflecting both trading activities and price movements.
- Asset Management Ratio Shift: Following this sale, Vail Resorts now represents only 1.73% of BAMCO's 13F reportable AUM, indicating investor concerns regarding the resilience of high-end vacation spending in an uncertain travel environment.
- Company Financial Overview: As of February 17, 2026, Vail Resorts' stock price stood at $137.75, down 8.9% over the past year, underperforming the S&P 500 by 23.36 percentage points, which reflects market caution regarding its future growth prospects.
- Profitability Model Analysis: Vail Resorts generates revenue primarily from lift ticket sales, lodging, and ancillary resort services; while the Epic Pass offers predictable cash flow, the company's high fixed costs mean that even slight declines in visitor numbers can significantly pressure earnings.
See More
BAMCO Inc Sells Shares of Vail Resorts
- Share Sale Details: BAMCO Inc sold 892,764 shares of Vail Resorts in Q4 for approximately $131.38 million, reflecting market concerns about high-end vacation spending, which has led to a decline in the company's investment position.
- Value Decline: The transaction resulted in a $214.19 million decrease in BAMCO's position value in Vail Resorts, with the current holding of 4,809,928 shares valued at $638.76 million, indicating pressure on the company within the luxury travel market.
- Portfolio Impact: Vail Resorts now represents 1.73% of BAMCO's 13F reportable assets under management, no longer being among the top five holdings, which suggests a weakening investor confidence in the company.
- Market Performance Analysis: As of February 17, 2026, Vail Resorts' stock price stood at $137.75, down 8.9% over the past year, underperforming the S&P 500 by 23.36 percentage points, reflecting a cautious market outlook on its future growth.
See More
Al Gore's Investment Firm Acquires Spotify Shares and Divests from Analog Devices
- Investment Changes: Generation Investment Management, co-founded by Al Gore, exited two semiconductor companies in Q4.
- New Acquisitions: The firm invested in shares of a trending streaming provider during the same period.
See More
Idexx Laboratories: A New Opportunity in Pet Health Investment
- Consistent Investment Returns: Since 1994, Idexx Laboratories has achieved an annual return of 20%, transforming an initial $5,000 investment into $1.6 million, demonstrating its strong performance and long-term investment potential in the pet health sector.
- Innovative Products Driving Revenue: The InVue DX instrument, successfully launched in 2025, saw nearly 6,400 placements within the year, expected to become one of the company's key products, particularly in the area of pet cancer detection, further driving revenue growth.
- Stable Recurring Revenue: In the most recent quarter, 92% of sales from Idexx's consumer animal group came from recurring revenue, ensuring stable cash flow and laying a solid foundation for future growth.
- Future Growth Potential: Idexx anticipates sales, earnings per share, and recurring revenue growth of 10%, 14%, and 8% respectively in 2025, and despite a current P/E ratio of 43, its stability and ongoing growth make it a compelling long-term investment.
See More
IDEXX Laboratories Reports Strong Q4 2025 Earnings Amid Target Revisions
- Strong Performance: IDEXX Laboratories reported Q4 2025 revenue of $1.09 billion, a 14% increase year-over-year, surpassing analyst expectations of $1.072 billion, demonstrating robust performance in the medical technology sector.
- Earnings Per Share Growth: The company’s earnings per share rose 18% to $3.08, exceeding the market estimate of $2.93, reflecting its sustained profitability and a gross margin of 61.7%.
- Core Business Growth: The companion animal segment grew 15% to $998 million, driven by strong instrument revenue, which surged 76% year-over-year, indicating robust market demand.
- Cautious Future Outlook: While IDEXX expects 2026 revenue between $4.63 billion and $4.72 billion, BTIG analysts noted a 200-basis-point drag from fewer pet visits among lower-income owners, although a 4% global price growth is anticipated.
See More
IDXX Options Trading Analysis and Risks
- Options Selling Risk: Selling puts on IDXX does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, necessitating careful risk-reward assessment.
- Yield Analysis: If IDXX's stock does not fall by 11.5%, the put seller only earns an 8.5% annualized return, with an effective cost basis of $540 per share after accounting for transaction costs.
- Historical Volatility: IDXX's historical volatility stands at 41%, and when combined with fundamental analysis, it aids investors in determining whether selling puts at the $560 strike price is worthwhile, balancing risks against potential rewards.
- Market Trading Dynamics: On Friday, the put volume among S&P 500 components reached 1.33 million contracts, matching call volume, indicating higher demand for puts than the long-term median, reflecting investor expectations of market volatility.
See More
